Decisions 15th October 2013


Recent JFG Decisions

 

At the meeting on the 15th October 2013 the following decisions / changes to the formulary were agreed

 

New Drug Requests

Approved

 

Lisdexamfetamine

  • Approved for inclusion, TLS Red, second line option for those patients who have had an inadequate response to methylamphetamine 

 

Levobupivacaine

  • Approved for inclusion onto the formulary, TLS Red

 

Dexmedetomidine

  • Approved for inclusion to the formulary for patients who are failing to wean from invasive ventilation with traditional management due to agitation

  

Ingenol

  • Approved for inclusion to the Joint Formulary on the grounds of efficacy, cost, and ease of administration.  TLS Green.  Solaraze to remain on formulary.

 

Ozurdex

  • Approved for inclusion to the Joint Formulary.

 

Rejected

 

Linaclotide

  • The decision to reject the original application made at the meting on the 10th September was upheld. 

 

Awaiting Financial agreement

 

Ferinject

  • Approved for inclusion to the Joint Formulary on the grounds of efficacy, cost, and reduction in administration time.  TLS Red.  Will be included in the formulary once there is confirmation of financial acceptance from the acute trusts. 

 

Shared Care Protocols

 

Rifaximin

  • The new SCP NOT accepted.  The JFG requested to await the NICE Technology appraisal due in January 2014

 

Rivaroxaban for Pulmonary Embolism

  • New SCP accepted, amber 1 month.

 

Methotrexate for IBD

  • Currently amber without a SCP.  The SCP nees to be sent around to the GPs for comment, and will be brought back to the next meeting.

 

Last updated by: on 09-12-2013 10:04